Frequently Asked Questions about ADMA Biologics, Inc. (ADMA)

Name: ADMA Biologics, Inc. (ADMA) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does ADMA Biologics, Inc. (ADMA) do?

Accepted Answer

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG...

Question 2

Is ADMA Biologics, Inc. (ADMA) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of ADMA reveals an Altman Z-Score of 11.25 and a Piotroski F-Score of 5/9. These metrics, combined with its 5-year revenue trend ($0.51B most recent), help investors decide if ADMA fits their risk profile.

Question 3

What is the current P/E ratio for ADMA?

Accepted Answer

As of the latest trading session, ADMA Biologics, Inc. (ADMA) has a trailing P/E ratio of 15.03.

Question 4

Who is the CEO of ADMA Biologics, Inc.?

Accepted Answer

The current Chief Executive Officer of ADMA Biologics, Inc. is Adam S. Grossman.

Question 5

What was ADMA's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, ADMA Biologics, Inc. reported annual revenues of $0.51B (2025), $0.43B (2024), $0.26B (2023), $0.15B (2022), $0.08B (2021) respectively.

Question 6

Does ADMA pay a dividend?

Accepted Answer

ADMA Biologics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does ADMA have?

Accepted Answer

In its latest reporting period, ADMA Biologics, Inc. generated $0.03B in Free Cash Flow against a total debt load of $0.08B.

Question 8

What is the Price-to-Book (P/B) ratio of ADMA Biologics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for ADMA Biologics, Inc. (ADMA) is currently 4.63.

Question 9

What is the Price-to-Sales (P/S) ratio of ADMA?

Accepted Answer

Based on trailing twelve-month data, ADMA Biologics, Inc. (ADMA) trades at a Price-to-Sales (P/S) ratio of 4.33.

Question 10

What is ADMA Biologics, Inc.'s Return on Equity (ROE)?

Accepted Answer

ADMA Biologics, Inc. (ADMA) has a Return on Equity (ROE) of 34.98%, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	624.2M	146.9M	477.3M	79.9M	-7.7M
2024-12	488.7M	139.7M	349M	82.1M	-21M
2023-12	329.2M	194M	135.2M	141.4M	90.1M
2022-12	348.5M	196.5M	152M	154.4M	67.9M
2021-12	276.3M	135.1M	141.2M	102.9M	51.8M

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	624.2M	146.9M	477.3M	79.9M	-7.7M
2024-12	488.7M	139.7M	349M	82.1M	-21M
2023-12	329.2M	194M	135.2M	141.4M	90.1M
2022-12	348.5M	196.5M	152M	154.4M	67.9M
2021-12	276.3M	135.1M	141.2M	102.9M	51.8M